

BOOK 1 TABLE OF CONTENTS

ILLUSTRATIONS IN THIS BOOK	IV
PSAP-VII EDITORIAL BOARD	V
WELCOME	VI
ACKNOWLEDGMENTS	VI
FACULTY POTENTIAL COI DISCLOSURE	VII
ROLE OF ACCP	VII
ROLE OF BPS	VII
CE AND PROGRAM INSTRUCTIONS	VIII
BOOK 1 POST TEST DIRECTIONS.....	VIII

Cardiology I	1
Cardiology I Panel	3
Cardiology I Subscriber Evaluation	5

HYPERTENSION: CLINICAL PRACTICE UPDATES By Heath R. Jennings, Pharm.D., BCPS (AQ Cardiology); and Terri S. Cook, Pharm.D., BCPS

Introduction.....	7
Overview.....	7
Evidence-Based Treatment.....	8
JNC 7 Guidelines 2003.....	8
AHA Scientific Statement 2007.....	8
ESC and ESH Guidelines 2007.....	12
CHEP 2008 and 2009.....	12
Changes Expected with the JNC 8.....	12
New Literature and Clinical Considerations.....	13
Special Patient Populations.....	13
Clinical Controversies.....	13
New Antihypertensive Therapies.....	14
Aliskiren.....	14
Nebivolol.....	14
Pipeline Agents.....	15
Additional Targets.....	15
Quality Improvement Programs.....	16
Home Blood Pressure Monitoring.....	16
The Pharmacist's Role in Preventing Clinical Inertia.....	17
Annotated Bibliography.....	17
Self-Assessment Questions.....	21

DYSLIPIDEMIAS: UPDATES AND NEW CONTROVERSIES

By Evan Sisson, Pharm.D., MSHA, CDE; and Benjamin W.
Van Tassell, Pharm.D., BCPS

Introduction.....	25
Risk of Cardiovascular Disease.....	25
Novel and Emerging Risks.....	26
Risk Calculators.....	28
Risks and Benefits of Treatment.....	28
Nonprescription Therapy—Therapeutic Lifestyle Change.....	28
Prescription Therapy.....	29
Populations Deserving Special Risk Consideration.....	32
Acute Coronary Syndromes.....	32
Cardiometabolic Risk.....	32
Elderly and Stroke Prevention.....	34

Pediatric Screening and Treatment.....	34
Quality Improvement—Pharmacist-Managed Programs.....	35
Annotated Bibliography.....	35
Self-Assessment Questions.....	39

MANAGEMENT OF CHRONIC STABLE ANGINA

By Paul P. Dobesh, Pharm.D., FCCP, BCPS (AQ
Cardiology); and Zachary A. Stacy, Pharm.D., BCPS

Introduction.....	43
Pathophysiology.....	43
Clinical Evaluation.....	44
Clinical Presentation.....	44
Physical Findings.....	44
Diagnostic and Prognostic Testing.....	44
Quality Patient Care.....	45
Goals of Therapy.....	45
Nonpharmacologic Treatments.....	45
Pharmacologic Treatments.....	46
Medical Therapy vs. PCI.....	48
Pharmacotherapy with Elective PCI.....	49
Monitoring.....	57
Conclusion.....	57
Annotated Bibliography.....	57
Self-Assessment Questions.....	61

VENOUS THROMBOEMBOLISM PREVENTION AND TREATMENT: EVIDENCE-BASED UPDATES

By Nancy L. Shapiro, Pharm.D., BCPS; and Adam J. Bursua,
Pharm.D., BCPS

Introduction.....	65
VTE Prophylaxis.....	65
Formal Strategy to Address VTE Prevention.....	66
Risk Stratification.....	66
Moderate-Risk Groups.....	66
General Surgery.....	66
Acute Medical Illness.....	68
High-Risk Groups: Orthopedic Surgery.....	70
VTE Treatment.....	72
Initial Treatment Choices.....	72
Warfarin Intensity.....	73
Therapy Duration.....	74
Heparins in Special Populations.....	76
Malignancy.....	76
Obesity.....	76
Kidney Considerations.....	77
Heparin-Induced Thrombocytopenia.....	78
Diagnostic Controversies.....	78
Treatment Approach and Therapeutic Options.....	78
The Future of Anticoagulation.....	79
Genetic Screening/Warfarin Dosing.....	79
Emerging Therapies.....	79
The Role of the Pharmacist.....	82
Annotated Bibliography.....	82
Self-Assessment Questions.....	87

Cardiology II	91
Cardiology II Panel	93
Cardiology II Subscriber Evaluation	95

EVOLUTION OF ANTITHROMBOTIC THERAPY USED IN ACUTE CORONARY SYNDROMES

By Sarah A. Spinler, Pharm.D., FCCP, FAHA, BCPS (AQ Cardiology)

Introduction.....	97
Timeline for Antiplatelet Development.....	97
Timeline for Anticoagulant Development.....	98
General Overview of ACS Therapy.....	98
Newer Antiplatelet Therapies for ACS.....	98
Clopidogrel Loading Dose.....	98
Prasugrel.....	107
Other P2Y12 Antagonists.....	109
Newer Anticoagulants for ACS.....	111
Bivalirudin for STEMI.....	111
Rivaroxaban.....	111
Apixaban.....	112
Quality Patient Care.....	113
Quality Metrics vs. Quality Performance Measures.....	113
ACC/AHA 2008 STE and NSTEMI	
Performance Measures.....	113
Estimating Bleeding Risk: The CRUSADE	
Bleeding Risk Score.....	114
Conclusion.....	115
Annotated Bibliography.....	115
Self-Assessment Questions.....	121

ATRIAL AND VENTRICULAR ARRHYTHMIAS: EVOLVING PRACTICES

By Cynthia A. Sanoski, Pharm.D., FCCP, BCPS

Introduction.....	125
Atrial Fibrillation.....	125
Epidemiology.....	125
Pathophysiology.....	126
Therapeutic Goals.....	128
Pharmacologic Therapy.....	128
Nonpharmacologic Therapy.....	132
Treatment Plan.....	133
Ventricular Arrhythmias and Related	
Emergency Cardiovascular Care.....	135
Epidemiology.....	135
Therapeutic Goals.....	137
Pharmacologic Therapy.....	138
Nonpharmacologic Therapy.....	139
Treatment Plan.....	139
Annotated Bibliography.....	142
Self-Assessment Questions.....	147

PERIOPERATIVE MANAGEMENT OF ANTITHROMBOTIC THERAPY

By Jeremy D. Flynn, Pharm.D., BCPS; and Kevin W. Hatton, M.D.

Introduction.....	153
Epidemiology.....	153
Therapeutic Goals.....	154

Perioperative Treatment of Patients Receiving VKAs.....	154
Assessment of Bleeding Risk.....	154
Assessment of Thromboembolic Risk During	
Interruption.....	155
Recent ACCP Recommendations.....	155
Emergency Reversal.....	156
Management of Perioperative Bleeding	
Associated with VKAs.....	157
Perioperative Treatment of Patients Receiving	
Antiplatelet Therapy.....	159
Bleeding Risk.....	159
Thromboembolic Risk During Antiplatelet	
Interruption.....	159
ACCP and AHA/ACC Recommendations.....	160
Management of Perioperative Bleeding	
Associated with Antiplatelet Agents.....	161
Issues Unique to Cardiac Surgery.....	162
Preoperative Considerations.....	162
Intraoperative Anticoagulation.....	162
Reversal of Anticoagulation After Separation	
from CPB.....	163
Bleeding Associated with Cardiac Surgery.....	165
Conclusion.....	165
Annotated Bibliography.....	165
Self-Assessment Questions.....	169

Cardiology III	173
-----------------------------	------------

Cardiology III Panel	175
-----------------------------------	------------

Cardiology III Subscriber Evaluation	177
---	------------

CARDIOVASCULAR DISEASE IN WOMEN

By Shannon W. Finks, Pharm.D., BCPS (AQ Cardiology)

Introduction.....	179
Sex-Related Differences and Gender Bias.....	179
Sex-Related Risk of CVD.....	180
Risk Awareness.....	180
Risk Factors.....	180
Cardiovascular Risk Equations for Women.....	183
CVD Among Women.....	186
Disease Presentation.....	186
Disease Findings.....	186
Diagnostic Testing Challenges.....	187
Prognosis and Treatment Outcomes.....	187
Treatment Disparity Among Men and Women.....	188
Evidence-Based Treatment Guidelines.....	190
Sex-Specific Drug Therapy.....	191
Role of the Pharmacist.....	194
Conclusion.....	194
Annotated Bibliography.....	195
Self-Assessment Questions.....	201

ANTICOAGULATION MANAGEMENT IN PREGNANCY

By Nathan P. Clark, Pharm.D., BCPS, CACP; and Mary Beth M. Dowd, Pharm.D., BCPS, CACP

Introduction.....	205
Pathophysiology.....	205
Risk Factors for VTE During Pregnancy.....	206

Thrombophilia Testing and Interpretation	206
Presentation and Diagnosis of VTE	206
Antithrombotic Drugs	208
Pharmacokinetic Alterations in Antithrombotic Drugs	
During Pregnancy	208
Risks	208
Implications for Nursing Mothers	209
Prevention of VTE	209
Antenatal VTE Prophylaxis	210
Postpartum VTE Prophylaxis	211
Thromboprophylaxis for the Pregnant	
Patient with MHV	212
Low-Molecular-Weight Heparin	212
Unfractionated Heparin	213
Warfarin	213
Treatment Recommendations	213
Treatment of VTE	213
Recommended Antithrombotic Agents	213
Thrombolysis and Vena Cava Interruption	214
Obstetric Complications	214
Treatment Recommendations	214
Management of Antithrombotic Drugs at Delivery	215
Role of the Pharmacist	216
Conclusion	216
Annotated Bibliography	216
Self-Assessment Questions	221

Surrogate Outcomes	241
Composite Outcomes	242
Basic Data Interpretation	243
Power and Sample Size	244
Analysis Selection	245
Survival Analyses	248
Non-inferiority Trials	249
Systematic Reviews and Meta-Analyses	250
Annotated Bibliography	250
Self-Assessment Questions	253
Reference Values for Common Laboratory Tests	258

EVALUATING DRUG-INDUCED CARDIOVASCULAR DISEASE: A PHARMACOEPIDEMIOLOGIC PERSPECTIVE

By **Brian J. Quilliam, Ph.D., RPh;** and **Marilyn M. Barbour, Pharm.D., FCCP, BCPS**

Introduction	225
Epidemiology of Adverse Events	225
Necessity of Postmarketing Evaluation of Safety	226
Pharmacoepidemiology	226
Pharmacovigilance	226
History of Pharmacovigilance	226
Pharmacovigilance Methodology	227
Pharmacoepidemiology	230
Cohort Studies	230
Case-control Studies	230
Large, Simple Trials	231
Evaluating the Risk of MI Associated with TZDs:	
An Example of the Role of Observational Studies	232
Observational Studies Evaluating TZDs and MI	232
Causality: Weighing All Available Evidence	234
Conclusion	235
Annotated Bibliography	235
Self-Assessment Questions	237

INTERPRETING DATA IN CARDIOVASCULAR DISEASE CLINICAL TRIALS: A BIOSTATISTICAL TOOLBOX

By **Ross T. Tsuyuki, BScPharm, Pharm.D., M.Sc., FCSHP, FACC;** and **Sipi Garg, M.Sc.**

Introduction	241
Types of Outcome Variables	241
Continuous and Discrete Variables	241